Skip to main content
2025 IDWeek Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Live Streamed
Live Streamed
On Demand
On Demand

A2. PK/PD studies

Poster Session: PK/PD Studies

(P-1248) Phase 2 Pharmacokinetics and Anti-Drug Antibody Results of the Investigational Twice-Yearly HIV-1 Treatment Regimen Lenacapavir, Teropavimab, and Zinlirvimab

Tuesday, October 21, 2025
12:15 PM - 1:30 PM US ET
Location: Poster Hall B4-B5

    Presenting Author(s)

  • NZ

    Nan Zhang, PhD

    Director of Clinical Pharmacology
    Gilead Sciences, Inc., Foster City, CA, USA
    Foster City, CA, United States

    • Co-Author(s)

  • JL

    Jianmin Li, MS

    Gilead Sciences, Inc., Foster City, CA, USA
    Foster City, California, United States

  • HL

    Hui Liu, PhD

    Director
    Gilead Sciences, Inc., Foster City, CA, USA
    Foster City, California, United States

  • KM

    Kwad Mponponsuo, MD, MSc

    Gilead Sciences, Inc., Foster City, CA, USA
    Foster City, California, United States

  • SC

    Sean E. Collins, MD, MS

    Gilead Sciences, Inc., Foster City, CA, USA
    Foster City, California, United States

  • YZ

    Yanan Zheng, PhD

    Gilead Sciences, Inc., Foster City, CA, USA
    Foster City, California, United States